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Systemic lupus erythematosus (SLE) is a multisystem
disease caused by antibody production and comple-
ment fixing immune complex deposition that results in
tissue damage. As many different antibodies can be pro-
duced in SLE patients, different organ-specific targets of
these antibodies can cause a wide spectrum of clinical
presentations, which are characterized by remissions
and exacerbations1. The pathogenic immune responses
are probably the result of environmental triggers acting
on certain susceptible genes. Ultraviolet light and cer-
tain drugs are the only known environmental triggers
identified to date1. Females of childbearing age have a
predilection for human SLE, clearly indicating that re-
productive hormones may play an important host role2.
The hypothesis that SLE activity is influenced by repro-
ductive hormones is supported by the findings that
disease flares increase during pregnancy3, and there is
an increased risk of development of SLE in women tak-
ing postmenopausal hormone therapy4. The age of onset
or diagnosis of most SLE patients is between 10 and 50
years old5. However, some investigators reported that
the uncommon late onset SLE patients have some dif-
ferences in clinical and laboratory features from the
younger patients6–20. Late onset SLE has been defined
as the disease onset occurring at ages older than 50,
55, 60 or 65 years6–20. However, some patients may not
be postmenopausal before 60 years of age. Therefore,
we identified late onset SLE patients with disease onset
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after 60 years of age in our hospital (Group A) and com-
pared these with an SLE patient group with onset at
15–40 years of age (Group B), the most common period
of disease onset, to determine if there are true differ-
ences between early and late onset SLE12. Mackay Me-
morial Hospital is a 1,900-bed medical center located
in Taipei, Taiwan.
Materials and Methods
We retrospectively identified 19 SLE patients with dis-
ease onset at age 60 or older (Group A) from 1998 to
2008 at Mackay Memorial Hospital according to the
inpatient and outpatient computerized database. For
comparison, we also included 50 SLE patients with dis-
ease onset between the ages of 15 and 40 (Group B) by
a simple random sampling method during the same
period from the same database. Sixty-nine patients in
total were analyzed in this study. All female patients
were postmenopausal in Group A. All patients were
Chinese, and they met at least four criteria of the 1997
American College of Rheumatology (ACR) updated cri-
teria for classification of SLE21. The age at disease
onset was defined as the date when the first recogniz-
able clinical manifestations of SLE appeared. The age at
the time of diagnosis was the date when the patients
met at least four ACR criteria and were diagnosed as
SLE by the physicians in this hospital.
In addition to the 11 criteria, fever, some significant
organ involvement, and laboratory data were further
used for evaluation of clinical and laboratory features
of SLE. The SLE disease activity index (SLEDAI)22 and the
numbers of SLE criteria fulfilled were used for measuring
the severity of disease when SLE was first diagnosed.
Laboratory assessment
Laboratory investigations included complete blood cell
count, erythrocyte sedimentation rate, C-reactive pro-
tein, liver enzymes, creatine phosphokinase, blood urea
nitrogen, creatinine, electrolytes, urinalysis, daily urine
total protein level, chest X-ray, electrocardiography, and
several special examinations such as an echogram and
computerized tomography, if needed.
Serologic tests included tests for rheumatoid factor
(nephelometric method), syphilis (Venereal Disease
Research Laboratory [VDRL] test), LE cell preparation,
antinuclear antibody (indirect immunofluorescence
method with HEp-2 cells as substrate), antibodies to
double-stranded DNA (anti-dsDNA; indirect immuno-
fluorescence with Crithidia luciliae as substrate, radioim-
munoassay or enzyme immunoassay), complements 3
and 4 (nephelometric method), antibodies to extractable
nuclear antigens (enzyme-linked immunosorbent assay
[ELISA]), anticardiolipin antibody (international stan-
dardized ELISA kit), and lupus anticoagulant (kaolin clot-
ting time and Russell viper venom test).
Statistical analysis
The data were analyzed statistically using Instat’s 
free software (www.ssc.rdg.ac.uk). Fisher’s exact test,
Student’s t test, Mann-Whitney test, and Wilcoxon rank
sum test were used to analyze the significant differ-
ences. Statistical significance was defined as p < 0.05.
Results
Records of 19 lupus patients in Group A (disease onset at
age 60 years or older) were analyzed and compared with
50 patients in Group B (disease onset, 15–40 years).
The female predominance was reduced in Group A
(p = 0.032) and the duration from disease onset to diag-
nosis was longer in Group A compared with Group B
(p = 0.008) (Table 1).
The eight clinical ACR updated criteria for classifica-
tion of SLE and significant organ involvement reported
at the time of diagnosis are listed in Table 2. The four
most frequent clinical manifestations of patients in
Group A were serositis (52.6%), arthritis (47.4%), malar
rash (42.1%) and nephritis (42.1%).
The incidence of renal insufficiency and mortality
rate were significantly higher in Group A compared with
Group B.
Listed in Table 3 are the other three laboratory ACR
updated criteria and some important laboratory fea-
tures not included in the ACR criteria but noted at the
time of diagnosis. The severity of SLE compared between
the two groups using SLEDAI and the numbers of ACR
criteria are also included in Table 3. The three most
frequent laboratory features in the late onset group
were antinuclear antibody (100%), hematologic disor-
der (84.2%), and immunologic disorder (73.7%). Only
the immunologic disorder rates, anti-dsDNA antibodies,
hypocomplementemia and anti-ribonucleoprotein (RNP)
antibodies, however, were significantly lower than in
Group A. Table 4 shows that the main cause of death
in both groups was septic shock.
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Discussion
Late onset SLE patients are relatively rare, as most cases
of SLE are females of childbearing age2. The female-to-
male ratio decreased in the elderly group, a finding
also cited previous reports12–20. The female-to-male
ratio was 2.8 in this study in the late onset group. It was
significantly smaller than that of the younger group
(15.7), and the results are in agreement with those re-
ported previously, probably resulting from a lack of sex 
Table 1. Basic demographics of systemic lupus erythematosus patients related to age at onset
Group A Group B
p*
(≥ 60 yr; n = 19) (≤ 40 yr; n = 50)
Male 5 3
Female 14 47
Female/male ratio 2.8:1 15.7:1 0.032
Age at onset, mean ± SD (yr) 70.4 ± 7.1 27.2 ± 6.5
Age at diagnosis, mean ± SD (yr) 70.9 ± 7.2 27.8 ± 5.5
Duration from onset to diagnosis (mo) 5.9 ± 5.3 2.2 ± 2.2 0.008
*p value from Fisher’s exact test and Student’s t test. SD = standard deviation.
Table 2. Clinical manifestations of systemic lupus erythematosus patients related to age at onset*
Group A Group B
p†
(≥ 60 yr; n = 19) (≤ 40 yr; n = 50)
Malar rash 8 (42.1) 21 (42.0) NS
Discoid rash 0 (0.0) 5 (10.0) NS
Photosensitivity 1 (5.3) 5 (10.0) NS
Oral ulcer 5 (26.3) 3 (6.0) 0.032
Arthritis 9 (47.4) 27 (54.0) NS
Serositis 10 (52.6) 14 (28.0) NS
Pleural effusion 7 (36.8) 10 (20.0) NS
Pericardial effusion 8 (42.1) 9 (18.0) NS
Nephritis 8 (42.1) 22 (44.0) NS
Renal insufficiency 8 (42.1) 2 (4.0) < 0.001
Proteinuria 8 (42.1) 20 (40.0) NS
Nephrotic syndrome 0 (0.0) 9 (18.0) NS
Hemodialysis 1 (5.3) 2 (4.0) NS
Neuropsychiatric 3 (15.8) 3 (6.0) NS
Lupus pneumonitis 3 (15.8) 3 (6.0) NS
Sjögren syndrome 1 (5.3) 2 (4.0) NS
Gastrointestinal vasculitis 2 (10.5) 4 (8.0) NS
Fever 3 (15.8) 16 (32.0) NS
Cancer 2 (10.5) 0 (0.0) NS
Mortality 6 (31.6) 4 (8.0) 0.022
*Data are presented as n (%); †p value from Fisher’s exact test. NS = not significant.
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hormone effects which predisposed younger females
to SLE. The lag time from disease onset to diagnosis was
significantly longer in the elderly group compared with
the younger group in this study (5.9 vs. 2.2 months),
and it is consistent with many previous reports10–16.
The authors of those studies commented that clinical
manifestations in the elderly SLE patients tended to be
more insidious, atypical and difficult to diagnose than
in younger patients. A delay in making the correct diag-
nosis or a wrong diagnosis often occurred, partly because
SLE was not considered to occur often in the elderly,
and partly because the clinical expression of the disease
differed to some extent in older patients10. The clinical
manifestations of late onset SLE varied in previous
reports and, therefore, different conclusions were drawn,
probably because of racial differences6–20. Our study
did not show significant differences in clinical features
between Groups A and B, except the renal insufficiency
rate, which was higher in the late onset group. These
study results contradicted previous results which found
that more serositis, lung involvement, Sjögren syn-
drome, less skin manifestations, photosensitivity, arthri-
tis, and nephritis occurred in elderly SLE patients23,24.
However, our results are in accordance with the report
of Mak et al.14, who reported that the clinical profile of
late onset SLE did not constitute a benign subgroup 
of the lupus population. There may be some bias in
information, selection and uncontrolled confounding
Table 3. Laboratory data of systemic lupus erythematosus (SLE) patients related to age at onset*
Group A Group B
(≥ 60 yr; n = 19) (≤ 40 yr; n = 50)
p†
Hematologic disorders 16/19 (84.2) 45/50 (90.0) NS
Hemolytic anemia 2/19 (10.5) 2/50 (4.0) NS
Leukopenia 10/19 (52.6) 25/50 (50.0) NS
Lymphopenia 15/19 (78.9) 44/50 (88.0) NS
Thrombocytopenia 5/19 (26.3) 7/50 (14.0) NS
Antinuclear antibody 19/19 (100) 50/50 (100) NS
Immunologic criteria 14/19 (73.7) 49/50 (98.0) 0.005
Anti-dsDNA antibody‡ 12/19 (63.2) 47/50 (94.0) 0.003
Hypocomplementemia 14/19 (73.7) 49/50 (98.0) 0.005
Anti-Sm antibody‡ 2/19 (10.5) 15/46 (32.6) NS
Anti-RNP antibody 2/18 (11.1) 21/44 (47.7) 0.009
Anti-Ro antibody 6/14 (42.9) 13/22 (59.1) NS
Anti-La antibody 4/14 (28.6) 5/22 (22.7) NS
LE cell 3/7 (42.9) 13/25 (52.0) NS
VDRL test§ 2/14 (14.3) 5/38 (13.2) NS
Anticardiolipin antibody‡ 1/12 (8.3) 4/22 (18.2) NS
Lupus anticoagulant‡ 2/13 (15.4) 5/33 (15.2) NS
Rheumatoid factor 5/15 (33.3) 14/33 (42.4) NS
SLEDAI 13.3 ± 8.2 14.1 ± 7.1 NS
SLE criteria 4.8 ± 0.8 4.9 ± 1.1 NS
*Data are presented as n (%) or mean ± standard deviation; †p value from Fisher’s exact test, and Mann-Whitney and Wilcoxon rank-sum tests;
‡positive test; §false-positive test. dsDNA = double-stranded DNA; RNP = ribonucleoprotein; VDRL = Venereal Disease Research Laboratory; SLEDAI =
systemic lupus erythematosus disease activity index. NS = not significant.
Table 4. The causes of death of systemic lupus erythe-
matosus patients related to age at onset*
Group A Group B
(≥ 60 yr; n = 19) (≤ 40 yr; n = 50)
Number of deaths 6 4
Septic shock 4/6 (66.7) 4/4 (100.0)
CVA† 1/6 (16.7) 0/4 (0.0)
Cancer‡ 1/6 (16.7) 0/4 (0.0)
*Data are presented as n or n (%); †brainstem stroke; ‡lung cancer
with bone metastasis. CVA = cerebrovascular accident.
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effects, such as racial differences, between this study
and the previous articles.
The laboratory features of the elderly SLE patients
in this study did not show significant differences from
the younger patients except less immunologic criteria
(anti-dsDNA antibody, hypocomplementemia, and anti-
RNP antibody). This is consistent with the reports of
Wilson et al.7 and Ballou et al.8, but contradicted a
pooled meta-analysis23 and a review article24, which
stated that there was a higher positive rate of rheuma-
toid factor, anti-Ro antibody and anti-La antibody in
late onset SLE. A significantly higher positive rate of
anti-RNP antibodies was noted in our study and in the
reports of Catoggio et al.9 and Maddison10, but clinical
correlations are still not clear. Less positive rates of anti-
dsDNA antibody and hypocomplementemia in late onset
SLE patients seemingly indicate a milder disease activ-
ity in our study. However, further comparison of disease
severity between Groups A and B using SLEDAI and the
numbers of SLE criteria did not show any significant
difference. The mortality rate in this study was signifi-
cantly higher in late onset SLE patients (p=0.022), which
is similar to some previous reports16,18,19. The most fre-
quent cause of death was septic shock in both groups
and was mostly related to median to large doses of
steroid treatment (0.5–2 mg/kg/day) or combined ther-
apy with immunosuppressives. This is similar to that
reported by Pu et al.16 but contradicts the results
reported by Bertoli et al.19 in that cardiovascular disease
is the leading cause of death in late onset SLE patients.
These findings again revealed that late onset SLE is not
necessarily a benign subgroup.
The limitations of our study and most of the previ-
ous reports are the sample size of rare late onset SLE
patients being small and the race being different in
different countries. These may have contributed to 
the differences in some results. More large-scale mul-
ticenter or international studies are needed for further
investigation.
In conclusion, late onset SLE patients had more in-
sidious onset, a longer lag time from disease onset to
diagnosis, higher rates of renal insufficiency and mor-
tality, lower positive rates of anti-dsDNA antibody, anti-
RNP antibody and hypocomplementemia, and lower
female predominance than the early onset patients.
The most frequent cause of death in both groups was
septic shock. Thus, this particular subgroup of SLE pa-
tients should be afforded greater attention to avoid
delayed diagnosis or misdiagnosis.
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